Group 1: Product Development and Market Focus - LiFSI is used as an additive in lithium-ion battery electrolytes, enhancing conductivity and thermal stability; currently in technical modification and customer trial phases [2] - The company is focusing on the core business of the Sanqi industry chain and ecosystem, considering both internal investment and external mergers and acquisitions to enhance resource integration [3] - The Shandong Lingkai project is in the technical modification and customer trial stage, with no revenue generated yet [4] Group 2: Financial Performance and Strategic Adjustments - The company has experienced significant performance declines and losses due to price reductions after core product bidding, adjustments in customer procurement strategies, and a strategic contraction of the steel structure business [4] - The company is actively divesting non-core business investments, including transferring subsidiaries and shares in Shanghai Lingkai and Tibet Kangyu [4] - The company is evaluating potential acquisitions, such as Sichuan Meifeng, which has a strong balance sheet and a low debt ratio of around 20% [3] Group 3: Innovation and Product Diversification - The company is committed to enhancing the stability and safety of drug efficacy, with successful clinical trials for Sanqi Tongshu capsules in treating ischemic stroke [4] - The company aims to strengthen its market position in the bottled water sector, holding the top market share in Chengdu and second in Sichuan [4] - The company is exploring new product development and strategic partnerships to diversify its product offerings [4] Group 4: Investor Relations and Future Outlook - The company assures that it is not at risk of delisting and is operating normally [4] - The management emphasizes that recent divestitures were strategic decisions aimed at consolidating resources to enhance core competitiveness and long-term profitability [4] - The company is continuously monitoring market opportunities and will make investment decisions based on strategic alignment and risk assessment [3]

Core Viewpoint - Huasheng Technology plans to publicly transfer 51% equity of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., for 42.5 million yuan, following a previous acquisition at 51 million yuan, indicating a strategic shift amid performance issues and regulatory scrutiny [1][4][6]. Group 1: Equity Transfer Details - The initial acquisition of 51% equity in Tibet Kangyu was completed for 51 million yuan in August 2023, with performance guarantees for net profits of 15 million yuan, 20 million yuan, and 25 million yuan for the years 2023 to 2025 [4]. - The transfer price has decreased from 63.78 million yuan to 42.5 million yuan over three attempts to sell the equity, reflecting a significant drop in perceived value [3][4]. - The first two attempts to transfer the equity in August 2023 did not attract any interested buyers, leading to a third attempt [3]. Group 2: Performance and Compliance Issues - In 2023, Tibet Kangyu met its performance commitments, but in 2024, it only achieved a net profit of approximately 16.78 million yuan, representing an 83.92% completion rate of the commitment [4]. - The company faced allegations of improper revenue recognition and internal control deficiencies, including recognizing revenue without actual product transfer and issues with expense reimbursements [5][6]. - In the first half of 2024, Tibet Kangyu reported a net profit of 458.43 million yuan, fulfilling only 18.34% of its annual profit commitment [5]. Group 3: Huasheng Technology's Financial Performance - Huasheng Technology experienced a significant decline in performance, with a reported revenue of 864 million yuan in 2024, down 13.89% year-on-year, and a net loss of 6.69 million yuan [6]. - In the first half of 2025, the company reported a revenue of 292 million yuan, a 36.29% decrease year-on-year, and a net loss of 54.84 million yuan, marking a 702.09% decline [6]. - The decline in performance is attributed to increased costs in its main product and a strategic reduction in its construction steel structure business [6].

Core Viewpoint - The company Huasheng Technology (000790) emphasizes the significance of its core traditional Chinese medicine product, Sanqi Tongshu Capsule, which is recognized as a national secondary protected variety of traditional Chinese medicine [1] Company Summary - Sanqi Tongshu Capsule is derived from the active components of Sanqi herb, specifically the effective part known as Sanqi saponins, which is used for its properties in promoting blood circulation and resolving blood stasis [1] - The product is classified as a new generation Sanqi formulation, with a clear material basis, defined active ingredients, and a well-understood mechanism of action [1] - Sanqi Tongshu Capsule has multiple therapeutic effects, including anti-platelet aggregation, prevention of thrombosis, improvement of cerebral ischemia, and promotion of neurological function recovery [1] - The product has evolved into a major traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases [1]

Core Viewpoint - Huasheng Technology (000790) emphasizes the prescription nature of its product, Sanqi Tongshu Capsule, and acknowledges the need for improved channel layout and refined operations in specific markets [1] Group 1: Market Strategy - The company plans to enhance market expansion efforts and improve product accessibility in key cities across the country [1] - Ongoing initiatives include strengthening supply chain collaboration and optimizing resource allocation dynamically [1] Group 2: Operational Focus - The company recognizes the potential for improvement in channel management and operational efficiency [1] - Continuous efforts are being made to refine channel management practices [1]

Core Viewpoint - Huasheng Technology has shifted its focus to the pharmaceutical sector while announcing the divestiture of its pharmaceutical distribution subsidiary, indicating a strategic realignment to enhance core business capabilities and profitability [2][3][4]. Group 1: Divestiture Details - Huasheng Technology plans to publicly transfer 51% of its stake in Tibet Kangyu Pharmaceutical Co., Ltd. at a base price of 63.78 million yuan [2][4]. - The company acquired this stake for 51 million yuan in August 2023, with performance guarantees tied to net profit targets for the subsequent years [2][6]. - The decision to sell comes before the end of the performance guarantee period, raising questions about the subsidiary's financial health [2][7]. Group 2: Financial Performance - In 2023, Huasheng Technology reported revenue of approximately 1 billion yuan, a year-on-year increase of 14.92%, with the pharmaceutical segment contributing about 511 million yuan, up 21.17% [6][9]. - However, in 2024, Tibet Kangyu failed to meet its profit commitments, achieving only 1.68 million yuan in net profit, representing a completion rate of 83.92% [7][8]. - The company's net profit has been declining, with a drop of 32.89% in 2023 and a projected loss of 45 to 55 million yuan in the first half of 2025 [9][11]. Group 3: Strategic Implications - The divestiture is part of a broader strategy to concentrate resources on core business areas, aiming to improve profitability and competitive strength [3][4]. - The sale will remove Tibet Kangyu's distribution business from Huasheng's consolidated financial statements, although the company's own product distribution will continue to be managed internally [9]. - The shift in revenue structure shows a significant increase in the pharmaceutical business's contribution to total revenue, rising from 48.33% to 73.74% over three years [9].

长江商报消息 ●长江商报记者 黄聪 并购反成业绩包袱，华神科技（000790.SZ）盈利能力持续下滑。 8月1日晚间，华神科技公告显示，公司拟挂牌转让控股子公司西藏康域51%股权，挂牌底价为6378.06 万元。 2023年8月，华神科技以5100万元收购西藏康域51%股权。然而，西藏康域未实现业绩承诺。 无独有偶，2022年6月，华神科技全资子公司以3320万元收购远泓矿泉水100%股权。远泓矿泉水业绩承 诺期（2022年至2024年）累计净利润为612.11万元，低于承诺的不低于1000万元。 因此，华神科技合计花费8420万元收购的西藏康域和远泓矿泉水，均未能完成业绩对赌。 自身业绩方面，2022年至2025年上半年，华神科技开启并购后，净利润已连续下滑三年半，而且近一年 半来预计亏损5169万元至6169万元。 溢价242.64%收购西藏康域 8月1日晚间，华神科技发布公告显示，基于战略发展规划和实际经营情况，为了进一步集中资源聚焦优 势业务，提升盈利能力和核心竞争力，公司拟在西南联合产权交易所公开挂牌转让控股子公司西藏康域 51%股权，上述股权出售首次挂牌底价以资产评估机构出具的评估价格为基准，即挂 ...

Core Viewpoint - Huasheng Technology (SZ000790) has received an administrative regulatory decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, leading to a requirement for corrective measures and warnings issued to key executives [2][4][5]. Group 1: Accounting Issues - The company has been found to have irregular accounting practices, including misclassification of advertising expenses as intangible assets by its subsidiary Hainan Rongsheng Hong Technology Co., Ltd. in 2021 [2]. - In 2023, another subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., recognized revenue from medical device sales without actual transfer of control to customers, leading to subsequent returns [2]. - Additionally, sales expenses from Chengdu Yuanhong Mineral Water Co., Ltd. were incorrectly accounted for in other subsidiaries, affecting performance assessment accuracy [2]. Group 2: Non-operational Fund Occupation - In 2021, Hainan Huasheng Development Holding Co., Ltd., a subsidiary, prepaid non-main business contract funds, which were later returned after five months, during which some funds flowed into companies controlled by the actual controller, constituting non-operational fund occupation [3]. Group 3: Internal Control Deficiencies - The internal control systems of the subsidiaries are inadequate, with issues such as improper expense reimbursement documentation and non-compliance with procurement management protocols [3]. - The company lacks a robust internal control system for large non-main business expenditures, leading to non-operational fund occupation in 2021 [3]. Group 4: Executive Accountability - Key executives, including Huang Mingliang (Chairman and President), Li Jun (Vice President and CFO), and Song Gang (Vice President), have been held responsible for the identified accounting and internal control issues [4][5]. Group 5: Company Performance - In 2024, Huasheng Technology reported revenue of 864 million yuan, a year-on-year decrease of 13.89%, and a net profit attributable to shareholders of -6.69 million yuan, down 124.19% [8]. - In the first quarter of 2025, the company achieved revenue of 127 million yuan, a decline of 29.21%, with a net profit of -14.59 million yuan, a drop of 740.09% year-on-year [9].

Core Viewpoint - The company is facing challenges in its financial performance for 2024, with a significant decline in revenue and net profit, primarily due to strategic business adjustments and ongoing project developments [2]. Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 13.89% year-on-year, resulting in a net profit loss [2]. - The decline in revenue and profit is attributed to the active contraction of the construction steel structure business, the ongoing trial production of the Shandong Lingkai project, and increased financial costs due to higher bank financing [2]. Group 2: Market Position and Competitive Advantage - The company has a strong market competitiveness and brand recognition in the pharmaceutical and health beverage sectors, with several products included in the medical insurance catalog [3]. - The company's health business segment, Huashen Blue Light, possesses rare mineral water resources, with its Biri 59 product having a silicate content of 59.99 mg/L, significantly exceeding national standards [3]. Group 3: Research and Development Focus - The company plans to focus on the in-depth exploration and secondary development of major traditional Chinese medicine products, particularly the Sanqi Tongshu capsules and Biyuan Shu, to enhance product application range and efficacy [4]. Group 4: Response to Industry Policy Changes - The company is closely monitoring changes in medical insurance payment reforms and drug procurement policies, aiming to enhance its risk resistance through market expansion and product quality management [5]. Group 5: New Market Expansion - The company is considering international market expansion based on its core traditional Chinese medicine products, which are recognized in the German Pharmacopoeia, while also planning to develop related health products and services [6]. Group 6: Asset Restructuring and Strategic Investment - The company will prudently evaluate asset restructuring and strategic investment opportunities based on its development strategy and market conditions [7].

Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 13.89%, resulting in a net loss due to intensified market competition and rising costs [3] - The decline in revenue and profit was primarily due to the contraction of the construction steel structure business and the ongoing trial production phase of the Shandong Lingkai project, which has not yet generated sales [3] Group 2: Market Position and Competitive Advantage - The company has a strong market presence in the pharmaceutical and health beverage sectors, with key products like Sanqi Tongshu Capsules and Biyuan Shu Oral Liquid included in the National Basic Medical Insurance Catalog [3] - The company ranks first in Chengdu's bottled drinking water market, leveraging unique mineral resources that enhance its product offerings [3] Group 3: Research and Development Focus - Future R&D efforts will concentrate on deepening the development of major traditional Chinese medicine products, particularly those with significant market influence [4] - The company aims to enhance product application range and efficacy stability through quality standard improvements [4] Group 4: Response to Industry Changes - The company is closely monitoring industry policy changes, such as medical insurance payment reforms, to ensure stable business development [4] - Strategies include expanding outpatient market channels and enhancing product quality management to mitigate policy risks [4] Group 5: Future Growth Strategies - The company is considering international market expansion based on strategic planning and market conditions, particularly for its core traditional Chinese medicine products [4] - Plans to extend the product line and develop related health products to meet diverse customer needs are in place [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 近日，国家药品监督管理局（以下简称"国家药监局"）网站发布《中药保护品种公告（第25号）（2025 年第45号）》，批准成都华神科技集团股份有限公司（以下简称"公司"）分公司成都华神科技集团股份 有限公司制药厂（以下简称"集团制药厂"）的三七通舒胶囊为首家中药二级保护品种，保护品种编号 为：ZYB2072025008，保护期限自公告日起七年。现将相关情况公告如下： 一、药品基本信息 药 品 名 称：三七通舒胶囊 剂型：胶囊剂 规格：每粒装0.2g 功能主治：活血化瘀，活络通脉，改善脑梗塞、脑缺血功能障碍，恢复缺血性脑代谢异常,抗血小板聚 集，防止血栓形成，改善微循环，降低全血黏度，增加颈动脉血流量，主要用于心脑血管栓塞性病症， 主治中风、半身不遂、口舌歪斜、言语謇涩、偏身麻木。 二、产品简介 公司核心中药产品三七通舒胶囊是国家原二类中药新药，是从三七药材中提取的活血化瘀类（三七三醇 皂苷）有效部位制剂，物质基础清楚、药效成分确切、作用机理明确，属于新一代三七制剂， ...